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The advent of new gene and cell therapies brings high promises to meet unmet medical needs. But, this also 
raises questions about how to produce these therapies cost effectively at scale. More specifically, producing 
enough high quality viral vector is key. Many early production and purification processes relied on techniques 
that are challenging to scale up, or are not commercially available at larger scales and sometimes even not 
compliant with cGMP. Scalable production and purification techniques from process development to cGMP 
compliant commercial manufacturing are therefore required. This feels like travelling back in time when the 
same challenges arose for the development of monoclonal antibodies. So instead of re-inventing the wheel, can 
we leverage lessons learnt from this past experience? Considering that processes for both mAbs and viral 
vectors include similar steps in term of cell culture, harvest, purification and formulation, the technologies 
developed and optimized for mAb manufacturing should therefore be applicable to viral vector processes. Here 
we will discuss the process similarities and differences for mAbs on one hand and adeno-associated viruses 
and lentiviruses on the other hand, focusing on gaps identified in developing process platforms for the 
production and purification of viral vectors. We will show how even the most recent advances in continuous 
bioprocessing for mAbs can be implemented quickly for viral vectors and the subsequent benefits generated in 
term of process productivity and economics. 
 
